Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex during vitrectomy/silicone oil surgery for PDR with DME
ChiCTR2000036080Phase 4Not yet recruiting
- Sponsor
- Beijing Aier Intech Eye Hospital
- Start
- Sep 2020
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of ozurdex in proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME) (2 arms), sponsored by Beijing Aier Intech Eye Hospital. Primary endpoint: Macular fovea thickness. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
ozurdex
03
Conditions
proliferative diabetic retinopathy (PDR)diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2000036080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000036080.